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Abstract
Objective—While systemic lupus erythematosus (SLE) and lupus nephritis (LN) 
disproportionately affect females, prior studies suggest that males may experience poorer 
outcomes. We investigated sex differences in healthcare utilization, end-stage renal disease 
(ESRD) and mortality among patients with LN receiving Medicaid, public insurance for low-
income individuals.
Methods—Within Medicaid Analytic eXtract (MAX) from 29 states (2000–2010), we used 
billing claims to identify individuals 5–65 years with incident LN (PPV 80%). MAX data were 
linked to the US Renal Data System to determine ESRD, and to Social Security Death Index files 
to determine death. We estimated adjusted incidence rate ratios (IRR) by sex for healthcare 
utilization using Poisson regression and used multivariable proportional hazards models to 
compare risks of ESRD and death by sex.
Results—Of 2750 patients with incident LN, 283 (10%) were male. Mean follow-up was 3.1 (SD 
2.3). Mean age was 25 (SD 14) years among males; 30 (SD 14) among females (p<0.01). Males 
had fewer outpatient (IRR 0.88, 95% CI 0.80–0.97) and emergency department visits (IRR 0.75, 
95% CI 0.63–0.90). The 5-year cumulative incidence of ESRD was 22.3% in males, 21.2% in 
females and of death, 9.4% in males, 9.8% in females. There were no sex differences in ESRD 
(HR 1.02, 95% CI 0.73–1.41, ref=females) or death (HR 0.81, 0.47–1.35).
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Conclusion—In this incident LN cohort, ESRD and mortality were extremely high overall, but 
not increased among males compared to females. In this vulnerable population, biologic and 
healthcare utilization differences by sex may not significantly affect outcomes.
Background
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that 
disproportionately affects females; the prevalence is 6 to 9 times higher compared to males.
(1, 2) Hypotheses for this female predominance include different environmental exposures, 
sex hormones, cell microchimerisms, and chromosome X dosage.(3) Prior studies suggest 
that while SLE is rare among males, their disease may be more severe and damage accrual 
greater.(4–6) Males with SLE have been shown to have more cytopenias, hemolytic anemia, 
cardiovascular disease and antiphospholipid antibodies, as well as more constitutional 
symptoms including fever and weight loss.(4, 6–8) In addition, a higher proportion of males 
may present with lupus nephritis (LN) at the time of SLE diagnosis, as well as during the 
disease course.(9, 10)
Few studies to date have examined differences in end-stage renal disease (ESRD) by sex. 
One study (N=93, 31 males), found no difference in end-stage renal disease (ESRD) or 
doubling of serum creatinine over approximately 40 months of follow-up, but did report that 
males experienced greater deterioration in renal function.(11) Another retrospective study of 
121 patients, 17 male, found that males had an increased risk of chronic renal insufficiency 
compared to females.(12) Two larger studies have been performed. In a U.S.-based academic 
cohort of 1979 patients with incident SLE (8% male), there were 13 cases of ESRD among 
males and 85 among females (OR 2.3, 95% CI 1.2–4.5). A similarly increased risk was 
found in a Taiwanese cohort of 4130 SLE patients, 11% of whom were male (HR for ESRD 
2.2, 95% CI 1.4–3.6 among men vs. women). Studies that have examined differences in 
mortality among SLE patients by sex have presented conflicting findings. One study 
including 408 SLE patients (69 males), demonstrated that mortality rates were higher among 
males, after adjusting for age, comorbidities and socioeconomic status (HR 1.55, 95% CI 
1.02–2.35).(13) Another study however, that used standardized mortality ratios of deaths 
observed to expected, found higher mortality among females with SLE.(14)
To our knowledge, there are no incident LN cohort studies in diverse, non-academic center-
based U.S. patient populations that have examined sex differences in ESRD or mortality. 
Similarly, while mortality is more than twice as high among patients with LN than SLE 
without LN, differences by sex are not well understood.(15) We aimed to study rates of 
ESRD and mortality in a diverse, nationwide cohort of incident LN patients enrolled in 
Medicaid, the U.S.-based public insurance covering >70 million low income individuals, to 
determine whether there were differences by sex. We hypothesized that rates of both ESRD 
and mortality would be higher among males. In addition, we aimed to examine healthcare 
utilization patterns among patients with LN prior to the development of ESRD. We 
hypothesized that healthcare utilization by males would be lower compared to females and 
potentially, that delays in care seeking would be related to ESRD, particularly in this 
vulnerable patient population.(16)
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Methods
Cohort identification
We utilized the Medicaid Analytic eXtract (MAX) with billing claims from all Medicaid 
beneficiaries from the most populated 29 U.S. states from 2000–2010. We identified 
children and adults aged 5–65 years with ≥3 SLE claims and ≥2 LN claims using a validated 
ICD-9 code-based algorithm for LN (PPV 80%).(17) We required ≥24 months of continuous 
enrollment in Medicaid with no LN-related codes (ICD-9 codes for glomerulonephritis, 
renal failure or nephrotic syndrome) prior to the first LN code (index date) for inclusion as 
incident LN.(1)
Outcomes
End-stage renal disease (ESRD)—To assess incidence of ESRD, we merged MAX 
data with the U.S. Renal Data System (USRDS) from 2000–2010. USRDS is a national data 
system that integrates demographic and diagnosis data as well as dialysis claims for nearly 
all patients in the U.S. who receive renal replacement therapy (dialysis or transplantation).
(18) In order for patients to be registered in the Centers for Medicare and Medicaid Services 
(CMS) ESRD database and to apply for Medicare eligibility, a renal provider must enroll the 
patient in USRDS and complete a Medical Evidence Report stating the primary cause of 
ESRD. Because most individuals in the U.S. with ESRD receive Medicare, Medicaid claims 
data alone do not allow for a comprehensive assessment of incident ESRD, requiring the 
linkage of these two databases to conduct our analyses. For our primary analysis, we 
included all cases of ESRD and for sensitivity analyses, we restricted our outcomes to 
exclude etiologies other than SLE nephritis and acute or chronic glomerulonephritis.
Mortality—Among ESRD patients enrolled in USRDS, a Death Notification Form must be 
completed by renal providers within 45 days of a death event and this is enforced by CMS. 
Therefore, for all patients in our cohort who developed ESRD, mortality was determined 
from USRDS. For incident LN patients enrolled in Medicaid who did not develop ESRD, 
death was determined using linked Social Security Death Index (SSDI) files. Cause of death 
was not available for this study for incident LN patients who died prior to ESRD.
Healthcare Utilization—We assessed healthcare utilization among all patients with 
incident LN using emergency department (ED) visits, outpatient visits and hospitalizations. 
In secondary analyses, we also examined these factors by sex specifically among those 
patients who developed ESRD, and among those who died, and restricting our cohort to 
adults only (≥18 years of age).
Covariates
We extracted all covariates during the 12-month period prior to and including the index date 
(date of first LN-related ICD-9 code). We assessed demographic factors including age, sex, 
race/ethnicity, geographic region, and ZIP code median household income from American 
Community Survey data (2006–2010) as a proxy for socioeconomic status (SES). We also 
examined medication use, specifically angiotensin-converting-enzyme inhibitors (ACE-I) or 
angiotensin II receptor blockers (ARBs), hydroxychloroquine, corticosteroids and 
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immunosuppressive medications (azathioprine, mycophenolate mofetil, methotrexate, 
leflunomide, cyclophosphamide, rituximab, tacrolimus, cyclosporine), as well as whether a 
renal biopsy was performed. We calculated the SLE-specific risk adjustment index, which 
has been shown to be a better predictor of inpatient mortality among patients with SLE than 
the Charlson comorbidity index.(19)
Statistical Methods
We compared baseline covariates between males and females using parametric and non-
parametric tests. We used Cox proportional hazards models to compare the risk of death 
(HR, 95% CI) between males and females. We used Fine and Gray proportional hazards 
models to compare the risk of ESRD while accounting for the competing risk of death 
(subdistribution hazard ratio (sdHR), 95% CI).(20) A competing risk (here, death), is an 
event that precludes the possibility of observing the event of interest (ESRD). Censoring 
patients at time of death, rather than accounting for death as a competing risk, may violate 
the assumption of noninformative censoring as these individuals who died are likely 
different from those individuals who survived. Proportional hazards models were adjusted 
for age, race/ethnicity, calendar year of the index date, zip code-level median household 
income, and the SLE-specific risk adjustment index. We did not include the SLE-specific 
risk adjustment index in our analyses of the ESRD outcomes as it includes chronic kidney 
disease and may lie on the causal pathway. We examined immunosuppressive and 
corticosteroid use and renal biopsies following the index date as well however we adjusted 
for these factors only during the baseline period (183 days prior to and including the index 
date) and not after as we suspect that they lie on the causal pathway and may mediate and 
not confound the relationship between sex and adverse outcomes. A mediation analysis was 
not feasible given our sample size. We tested the proportional hazards assumption (sex 
multiplied by the natural log of time) and did not find violations in our models. We 
conducted additional sensitivity analyses to examine whether there were differences between 
the spacing between the first SLE code in our dataset and the first LN-related code by sex. 
We did not conduct this as a primary analysis given the limitation of including patients with 
prevalent SLE without knowledge of when their first-ever SLE code occurred. We used 
Poisson regression to calculate incidence rates (IR, 95% CI) and incidence rate ratios (IRR, 
95% CI) of healthcare utilization (ED visits, outpatient visits and hospitalizations) in the 
cohort overall and then in secondary analyses among those who developed ESRD and 
among those who died. IRRs were adjusted for age, race/ethnicity, ZIP code median 
household income, SLE-specific risk adjustment index and calendar year of the index date.
All analyses were performed using SAS 9.3 (SAS Institute Inc. Cary, NC). We obtained 
Data Use Agreements for this study from both CMS and USRDS and data are presented 
according to Federal reporting standards (cell sizes <11 are suppressed). The Partners 
Human Research Committee at Brigham and Women’s Hospital approved this study. All 
patient information was de-identified prior to our receipt of the data and therefore informed 
consent was not possible or required.
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Results
We identified 2,467 females and 283 males with incident LN enrolled in Medicaid between 
2000–2010. The mean ± SD age was 29.6 ± 13.9 among females, 24.7 ± 14.1 among males 
(p<0.01) and 37% of males were 12–17 years of age compared to 18% of females. (Table 1). 
The mean ± SD follow-up for both sexes was 3.1 ± 2.3 years. The cohort was racially and 
ethnically diverse and well-distributed geographically across the U.S. The ZIP code median 
household income was similar for both sexes. Baseline medication use (ACE-I/ARBs, 
hydroxychloroquine, immunosuppressives and corticosteroids) and renal biopsies in the 12 
months prior to and including the index date, were similar for males and females. We also 
examined ACE-I/ARB, immunosuppressive medication and corticosteroid use and renal 
biopsies following the index date. Among patients who were followed until ESRD, a slightly 
higher percentage of males received immunosuppressive medications compared to females 
(64% vs. 58%), and received ACE-I/ARBs (76% vs. 66%). More females than males had 
renal biopsies (38% vs. 29%). There was minimal difference in corticosteroid use (79% 
among females vs. 80% among males). Among patients who were followed until death, 60% 
of females received immunosuppressives compared to 67% of males, 68% of females 
received ACE-I/ARBs compared to 77% of males, and 40% of females had a renal biopsy 
compared to 31% of males. Steroid use was comparable (80% among females vs. 81% 
among males).
Outcomes by Sex
In our incident LN cohort, we identified 394 cases of ESRD, 353 in females and 41 in males. 
The mean ± SD time to ESRD was 2.03 ± 1.8 years in females and 1.97 ± 1.8 years in 
males; the median time was 1.6 years in both groups. The primary cause of ESRD was LN 
for 295 patients, over 75% of both males and females (Supplemental Table 1), and other 
forms of nephritis comprised 10% of male cases and 5% of female cases. Hypertensive 
chronic kidney disease and diabetic nephropathy were the most common other etiologies. 
There were 190 deaths (174 among females, 16 in males). The mean ± SD time to death was 
1.82 ± 1.9 years among females and 1.88 ± 1.5 years among males; the median time was 1.1 
years for females and 1.8 years for males. Among patients with ESRD, 95 (86 females, 9 
males) died following this diagnosis.
The yearly cumulative incidence of both ESRD and death was comparable for both sexes 
(Table 2). In the multivariable Fine and Gray proportional hazards model, adjusted for age, 
race/ethnicity, calendar year and median household income and accounting for the 
competing risk of death, there was no difference in ESRD comparing males to females 
(sdHR 1.05, 95% CI 0.76–1.45) (Table 3). We did observe an increased risk of ESRD among 
black patients compared to white (sdHR 1.37, 95% CI 1.02–1.84).
In the multivariable Cox proportional hazards model examining risk of death, after adjusting 
for age, race/ethnicity calendar year and median household income, we did not find a 
difference between males vs. females (HR 0.97, 95% CI 0.58–1.62). There was a non-
statistically significant trend towards a reduced risk of death among males vs. females when 
the model was additionally adjusted by the SLE-specific risk adjustment index (HR 0.81, 
95% CI 0.47–1.35). We observed an increased risk of death among older patients and a 
Feldman et al. Page 5
Arthritis Rheumatol. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
reduced risk among Hispanic patients. We observed an increased risk of death among 
patients in the lowest median household income quartile (HR 1.56, 95% CI 1.02–2.36), 
however this risk was attenuated after adjusting for the SLE-specific risk adjustment index 
(HR 1.51, 95% CI 0.99–2.30). LN patients with higher SLE-specific risk adjustment indices 
had an increased risk of death (HR 1.14, 95% CI 1.10–1.19). In secondary analyses, we 
examined only those patients who developed ESRD attributed to LN by their attending 
nephrologist at the time of USRDS enrollment, and among those with diagnoses of LN or 
any other nephritis. We similarly did not find statistically significant differences in our 
adjusted models by sex for either ESRD or death. We did two additional sensitivity analysis 
examining both outcomes only among males and females who received immunosuppressives 
during the baseline period, and among those who had a renal biopsy and similarly found no 
differences by sex in either ESRD or death.
In additional sensitivity analyses, we examined time between first SLE code in our dataset 
and first LN-related code. We found that the median (IQR) time between first SLE code and 
first LN-related code was 62 (0, 503) days for females with 26% occurring on the same date, 
compared to 13 (0, 173) days for males with 38% on the same date. Among the females who 
developed ESRD, 27% had the first SLE code on the same date as the first LN code 
compared to 34% of the males. Among the females who died, 30% had the first codes on the 
same date compared to 19% of males. We conducted stratified analyses separating males and 
females with their first SLE and LN codes on the same day from those with any separation, 
and then also stratified on <30 days (vs. ≥30 days) and <60 days (vs. ≥60 days) and did not 
find any statistically significant differences in ESRD or death by sex.
Healthcare Utilization by Sex
After adjusting for age, sex, race/ethnicity, year, region, household income and SLE risk-
adjustment index, males had lower rates of ED visits (IRR 0.75 95% CI 0.63–0.90) and 
outpatient visits (IRR 0.88, 95% CI 0.80–0.97) compared to females (Table 4). Rates of 
hospitalizations were also lower among males compared to females, but the IRR adjusted for 
age, race/ethnicity, year, median household income and SLE-specific risk adjustment index 
was not significantly different (IRR 0.85, 95% CI 0.71–1.02). In secondary analyses, we also 
examined utilization restricted to adults 18–65 years. We similarly found reduced incidence 
rates of outpatient visits among adult males compared to females (IRR 0.86, 95% CI 0.75–
0.99) but no statistically significant difference in ED visits or hospitalizations.
In additional secondary analyses, examined utilization specifically among patients with LN 
who developed ESRD and among those who died in the period between the index date and 
the outcome of interest (Tables 5 and 6). We did not find statistically significant differences 
in ED visits, outpatient visits or hospitalizations by sex in either of these groups. However, 
among patients who developed ESRD and among patients who died, we did observe a trend 
towards greater hospitalizations and fewer ED visits prior to the outcomes among males 
compared to females.
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Discussion
In this high-risk low-income population of Medicaid beneficiaries with incident LN, we 
observed extremely high rates of ESRD and mortality overall. Contrary to prior studies that 
suggested increased risk of adverse outcomes among males with SLE compared to females, 
in this cohort, rates of ESRD and mortality did not differ by sex. Healthcare utilization, and 
particularly ED visits and outpatient visits, was less frequent for males compared to females 
overall among patients with incident LN, but comparable among those patients who 
developed ESRD or who died.
Overall, compared to other cohorts, the cumulative incidence of ESRD and mortality was 
substantially higher among this population of Medicaid beneficiaries. In the Systemic Lupus 
International Collaborating Clinics (SLICC) inception cohort, among patients with LN, the 
10-year cumulative incidence of ESRD was 10.1% (95% CI 6.6–13.6), compared to the 5-
year cumulative incidence in our cohort of 22.3% (95% CI 16.0–29.3) among males and 
21.1% (95% CI 19.0–23.5) among females.(9) The SLICC 10-year cumulative incidence of 
death was 5.9% (95% CI 3.3–8.4) among patients with incident LN, compared to the 5-year 
cumulative incidence of 9.4% (95% CI 5.4–14.9) in males and 9.8 (95% CI 8.3–11.5) among 
females in our cohort.(9) There are several plausible explanations for the increased burden of 
adverse outcomes observed. The Medicaid population is a low-income population shown to 
have significant comorbidities and adverse SLE-related outcomes overall.(15, 21) In 
addition, the quality of care provided to Medicaid beneficiaries with LN has been shown to 
be suboptimal.(22) Patients with LN-related ESRD have been demonstrated to have poor 
post-ESRD care as well.(23) Care among Medicaid beneficiaries may be inconsistent given 
state-to-state differences in continuous enrollment policies and eligibility and within the 
Medicaid SLE population, medication adherence has been shown to be poor, and acute care 
utilization to be high.(24) In contrast, the SLICC network is comprised of academic medical 
centers and patients have been shown to receive standard of care treatments and sustained 
follow-up over the course of their 12-year follow-up period.(9) The racial/ethnic makeup of 
the two cohorts is also distinctly different with a significantly higher percentage of black 
individuals in our cohort, and lower percentage of both white and Hispanic individuals 
compared to SLICC, which may affect differences in quality of care received as well as 
outcomes.(23) In addition, the Medicaid population may be enriched with a more severe 
SLE phenotype as patients with more aggressive disease may lose their jobs, or be unable to 
work, and therefore be more likely to receive public health insurance.
Within a cohort of 344 incident SLE patients in Atlanta, Georgia, the 5-year cumulative 
incidence of ESRD was 5.2% overall, but only approximately one-third of these patients had 
early LN at the time of SLE diagnosis.(25) The proportion of ESRD was higher among 
blacks compared to whites (6.4% compared to 2.5%), and significantly higher than other 
SLE cohorts in Taiwan and Japan, in which it was approximately 3%.(26, 27) While it is 
challenging to compare these estimates to LN patients within Medicaid, our finding of 
ESRD burden was approximately four times higher than that of the Georgia cohort, which is 
more than what might be expected if only the third with LN had progressed. In the Georgia 
cohort, 79% of patients had ESRD attributed to SLE as reported by USRDS.(28) In our 
cohort, this proportion was similar.
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In the current study, we found comparable rates of ESRD and mortality by sex. Findings 
from prior studies have varied; some demonstrated increased rates among males, and some 
like ours, found no significant differences by sex. Male sex was not associated with ESRD 
incidence in a study in the Georgia Lupus Registry.(25) In a Taiwanese SLE cohort, there 
was an increased risk of ESRD among males compared to females (HR 2.2, 95% CI 1.4–
3.6).(26) In the Hopkins cohort, there was a doubled odds of renal biopsy, renal insufficiency 
and renal failure among males compared to females, adjusting for age, duration of SLE, 
ethnicity and smoking status.(4) In that cohort, male sex was also associated with two times 
greater risk of death.(29) In a U.S.-based inception cohort of approximately 400 patients, 
17% male, in models adjusted for age, race, insurance status and area-level socioeconomic 
indicators, male sex was associated with increased risk of death.(13) It is challenging to 
compare findings across studies however, given the variation in patient populations by age, 
race/ethnicity and by academic vs. non-academic care setting, differences in inclusion of 
incident vs. prevalent SLE or LN cases, and sparse numbers of male SLE cases. While other 
studies suggest that outcomes may be poorer among males of non-White race/ethnicity, we 
lacked the power to substratify in order to investigate this question in our patient population.
(4)
In keeping with prior studies, we found an increased risk of ESRD among black patients 
with LN overall compared to white.(25, 30) This has been attributed both to genetic factors 
(e.g. APOL1 G1 and G2 nephropathy alleles) as well as healthcare access and utilization 
factors.(23, 25, 31) We also found a decreased risk of death among Hispanic patients, which 
has been previously demonstrated in the Medicaid SLE population.(15) While we did not 
observe an association between lower ZIP code-level median household income and ESRD, 
we did see a relationship with mortality. LN patients living in the poorest areas did have an 
increased risk of death compared to those in the highest quartile. This finding is with the 
caveat that nearly all patients in this cohort would be classified as poor as this is part of the 
eligibility criteria for enrollment in Medicaid. This association between lower ZIP code 
median household income and death was attenuated after adjusting for SLE-related 
comorbidities. The relationship between area-level poverty and accrual of SLE-related 
damage resulting in adverse outcomes is in line with a prior study that similarly affirms the 
detrimental effects of poverty among patients with SLE.(32)
We originally hypothesized that an explanation for sex differences in outcomes seen in prior 
studies may in part be related to differences in healthcare utilization. In the general 
population, females have more regular contact with the healthcare system at younger ages 
because of pregnancy and increased preventive health measures (e.g. cervical and breast 
cancer screening) (33) and therefore SLE may be detected earlier and at a less severe state. 
Older male adolescents (age 16–20 years) have also been shown to have significantly fewer 
ambulatory care visits both compared to younger males and compared to females of the 
same age.(34) While we did not find differences in ESRD or mortality in our cohort, we did 
find that males overall had lower rates of ED visits and outpatient visits compared to 
females. When we restricted our cohort only to adults, we similarly found lower rates of 
outpatient care utilization among males compared to females. Further studies are needed to 
delineate whether this difference is related to behavioral differences or SLE disease 
manifestations and severity, and whether these patterns may contribute to variation in other 
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outcomes beyond ESRD and mortality. We did find that a greater percentage of males had 
their first SLE code in our dataset on the same date as their first LN-related code compared 
to females (38% vs. 26%). However, in stratified analyses, we did not observe differences in 
either ESRD or mortality by sex when we separately examined those with less versus more 
spacing between codes. Since this was an incident LN cohort within a prevalent SLE cohort, 
the interpretation of this sensitivity analysis is limited and further studies are needed to 
understand the relationship between duration of SLE at the time of LN and sex differences 
in outcomes.
There were limitations to our study. The use of claims data did not allow us to assess lab 
values or disease activity. Antiphospholipid antibody status is not available using ICD-9 
codes, however we did not observe statistically significant differences in warfarin use by sex. 
Despite using a conservative definition for LN with high PPV, and requiring two years 
without codes to identify incident cases, there may have been some misclassification with 
prevalent LN. In this cohort, males were younger than females at LN onset and a smaller 
proportion were Black, which may have contributed to our non-significant differences in 
ESRD and mortality in males vs. females. However, in models fully adjusted for age, race/
ethnicity, SES and the SLE risk-adjustment index, we still did not observe an increased risk 
of ESRD or death among the males. In addition, race/ethnicity may modify the relationship 
between sex and adverse outcomes however we lacked sufficient power to investigate this 
question in depth. While our cohort included more males than most studies to date, and 
unfortunately, adverse outcomes were not uncommon, we still may have been underpowered 
to detect differences by sex. In addition, while there were no significant differences in 
medication use or renal biopsy rates by sex prior to and including the index date, males 
received more immunosuppressive medications and ACE-I/ARBs following the index date, 
and underwent fewer renal biopsies. Immunosuppressive therapy and ACE-I/ARBs are 
contraindicated in pregnancy and thus are likely be more limited in use among women of 
reproductive age. Fewer biopsies among males may relate to lower rates of outpatient care 
utilization that we observed among males compared to females. However, from the data 
available, it is not possible to decipher whether the lower percentage of males who 
underwent renal biopsy was due to patient preference, lower quality of care for males 
compared to females, or more severe disease on presentation that was treated without biopsy. 
Given our sample size, and specifically, the small number of males receiving 
immunosuppressive medications who had the outcomes of interest, we were unable to do 
mediation analyses. We chose not to adjust for these factors in our proportional hazard 
models as we felt that they were likely to lie on the causal pathway. In addition, overall use 
of immunosuppressive medications and hydroxychloroquine, the standard-of-care treatments 
for patients with lupus nephritis, was low in this cohort. Previous work in the Medicaid 
population has affirmed this finding as well.(21, 22, 35) While we did conduct sensitivity 
analyses examining adverse outcomes restricted to patients who received 
immunosuppressive medications and did not find significant differences by sex, we cannot 
determine whether differences would be apparent if the entire cohort received standard-of-
care regimens. We did demonstrate the ill effects of likely severe, poorly managed disease, 
and the reality that differences by sex may be less pronounced in this setting. Further studies 
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are needed to investigate the role of sex differences in care practices and medication use, and 
the direct impact of these factors on outcomes.
This study also had a number of strengths. We included a racially and ethnically diverse 
population of low-income high-risk individuals with a relatively large number of male SLE 
patients. Our Medicaid data were linked to USRDS, which captures nearly all ESRD cases 
in the U.S. While our findings may not be generalizable to all populations, we focused our 
study on a large, vulnerable and diverse patient population, shown in other studies to suffer 
from an excess burden of adverse outcomes, receiving care at both academic and non-
academic centers.(21, 35, 36) With 10 years of data and a mean follow-up of approximately 
3 years, we were able to capture high rates of ESRD and mortality in this population overall 
and demonstrate no statistically significant difference by sex. We cannot rule out the 
possibility of differences by sex among patients either with less severe disease and slower 
progression, or among patients who consistently receive timely, standard-of-care evaluation 
and treatment. However, the findings of this study are in line with prior work in the same 
vulnerable population and suggest the need for dedicated efforts to improve access to high 
quality care for these patients.
In this large, nationwide study of Medicaid beneficiaries with incident LN, we found 
extremely high rates of ESRD and mortality but no statistically significant differences by sex 
in these outcomes. While males had lower rates of emergency department and ambulatory 
care visits, we did not observe differences in these severe adverse outcomes. It is plausible 
that in this especially vulnerable population with overall poor access to high quality care, 
biologic differences may be less relevant in shaping adverse outcomes. This contrasts with 
academic-based cohort studies where most patients receive consistent, standard-of-care 
therapy. Ongoing studies with extended follow-up and increased numbers of male SLE 
patients are needed to further investigate the role of genetic and environmental factors, as 
well as healthcare quality and use in SLE-related outcomes by sex. The profoundly high 
rates of ESRD and mortality in this vulnerable population, and the increased risk of death 
seen among patients living in the poorest areas provide further evidence that heightened 
efforts are needed to improve care for these patients.
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Table 1
Baseline characteristics of incident lupus nephritis cohort by sex
Characteristics
N=2750
Female
N=2467
Male
N=283
p-value
Age (years) at LN- mean ± SD 29.6 ± 13.9 24.7 ± 14.1 <0.01
Age group – N (%)
  5–11 years 129 (5.2) 24 (8.5)
  12–17 years 442 (17.9) 103 (36.8)
  18–34 years 1144 (46.4) 95 (33.6)
  35–50 years 492 (19.9) 39 (13.8)
  51–65 years 260 (10.5) 21 (7.4)
Race/Ethnicity- N (%) <0.01
  Black 1351 (54.8) 124 (43.8)
  White 449 (18.2) 59 (20.9)
  Hispanic 460 (18.7) 73 (25.8)
  Asian 126 (5.1) 21 (7.4)
  AI/AN 32 (1.3) NR
  Other 49 (2.0) NR
Region- N (%) 0.06
  South 999 (40.5) 102 (36.0)
  Northeast 467 (18.9) 72 (25.4)
  Midwest 470 (19.1) 48 (17.0)
  West 531 (21.5) 61 (21.6)
Zip code median household income-mean/10,000 ± SD 4.3 ± 1.6 4.4 ± 1.6 0.36
SLE risk adjustment index – mean ± SD 3.6 ± 2.9 3.8 ± 3.1 0.29
Hydroxychloroquine use – N (%) 1216 (49.3) 124 (43.8) 0.08
Corticosteroid use – N (%) 1778 (72.1) 197 (69.6) 0.38
Immunosuppressive use – N (%) 968 (39.2) 118 (41.7) 0.42
ACE-I/ARB use – N (%) 1180 (47.8) 149 (52.7) 0.12
Renal biopsy – N (%) 927 (37.6) 17 (41.3) 0.22
NR= not reported; cell sizes <11 suppressed per CMS regulations
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Table 3
Comparative risks of ESRD and mortality by sex in multivariable adjusted models
Covariates Model 1*
HR (95% CI)
Model 2**
HR (95% CI)
Model 3+
HR (95% CI)
Outcome: ESRD
Sex (ref=female)
  Male 1.06 (0.76–1.46) 1.05 (0.76–1.45)
Age 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Race (ref=white)
  Black 1.35 (1.01–1.80) 1.37 (1.02–1.84)
  Hispanic 0.97 (0.67–1.39) 0.97 (0.68–1.40)
  Asian 0.75 (0.42–1.35) 0.75 (0.42–1.35)
  AI/AN 1.85 (0.83–4.11) 1.86 (0.84–4.15)
Median household income (ref=highest quartile)
  Quartile 1 (lowest) 1.09 (0.82–1.45)
  Quartile 2 0.93 (0.69–1.26)
  Quartile 3 1.04 (0.77–1.40)
SLE risk adjustment index
Outcome: Mortality
Sex (ref=female)
  Male 0.95 (0.57–1.59) 0.97 (0.58–1.62) 0.81 (0.47–1.35)
Age 1.04 (1.03–1.05) 1.03 (1.02–1.04) 1.02 (1.01–1.03)
Race (ref=white)
  Black 1.13 (0.78–1.63) 1.03 (0.71–1.50) 1.09 (0.74–1.60)
  Hispanic 0.50 (0.28–0.89) 0.47 (0.26–0.85) 0.50 (0.28–0.91)
  Asian 0.75 (0.33–1.67) 0.77 (0.34–1.74) 0.86 (0.38–1.94)
  AI/AN 1.84 (0.66–5.16) 1.56 (0.55–4.41) 1.84 (0.65–5.24)
Median household income (ref=highest quartile)
  Quartile 1 (lowest) 1.56 (1.02–2.36) 1.51 (0.99–2.30)
  Quartile 2 1.26 (0.82–1.93) 1.29 (0.84–1.98)
  Quartile 3 1.03 (0.66–1.62) 1.07 (0.68–1.68)
SLE risk adjustment index 1.14 (1.10–1.19)
*
Model 1 adjusted by age, race/ethnicity and calendar year of index date
**
Model 2 adjusted by age, race/ethnicity, year and median household income (zip code-level) in quartiles
+
Model 3 adjusted by age, race/ethnicity, year, median household income (zip code-level) and SLE-specific risk adjustment index [Not performed 
for ESRD as the risk adjustment index includes renal severity measures]
Bolded values indicate p<0.05, AI/AN=American Indian/Alaska Native
ESRD models account for the competing risk of death and hazard ratios (HR) represent subdistribution hazard ratios from Fine and Gray 
proportional hazard models
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